RE: Nuformix Secures U.S. Orphan Drug Designation for IPF Therapy Candidate NXP00211 Mar 2026 07:55
This is just massive news, the next step to full authorisation, the company has never been at this stage, the years of hard work has now paid off.
This is tNOT the company stating it, its the world regulatory body stating where we are.
All for a £5.5m market cap